More ADA coverage from FierceMedicalDevices

@FierceBiotech: Special report via FiercePharma.com: 10 Top-selling Diabetes Drugs - 2012. Feature | Follow @FierceBiotech

 @JohnCFierce: ICYMI Friday: Can Novartis gain anything from its latest breakthrough drug win at the FDA? Article | Follow @JohnCFierce

@RyanMFierce: Novo Nordisk's R&D chief sizes up diabetes rivals and scandal-wary FDA. Editor's corner | Follow @RyanMFierce

Medical Device News

@FierceMedDev: J&J's Animas reveals positive artificial pancreas data. Story | Follow @FierceMedDev

@DamianFierce: From , Medtronic's new sensor-outfitted insulin pump cuts rates of nighttime hypoglycemia. Story | Follow @DamianFierce

> Medtronic leaps toward artificial pancreas with MiniMed study

Medtronic's ($MDT) sensor-integrated insulin pump maintained reduced overnight hypoglycemia rates in patients with Type 1 diabetes in a new study, results the company said are a major step toward developing an artificial pancreas. In the study, Medtronic tested 247 diabetics, outfitting about half of them with its MiniMed integrated system, which pairs continuous glucose monitoring with insulin infusion, and the other half with a standard insulin pump. In results released at the weekend's annual meeting of the American Diabetes Association, the combo device reduced the rates of nocturnal hypoglycemic events by 31.8% and lowered magnitude and duration by 37.5%, all with no serious adverse events. Read the full story >>

> J&J's Animas reveals positive artificial pancreas data

Johnson & Johnson's ($JNJ) Animas division revealed positive results Friday from the second phase of clinical trials for its artificial pancreas candidate, demonstrating that the device maintained safe glucose levels overnight. The Hypoglycemia-Hyperglycemia Minimizer System (HHM) is a closed-loop glucose-control device that combines a standard insulin pump with continuous glucose monitoring designed to mimic the function of a healthy pancreas. Animas presented the new data at the annual meeting of the American Diabetes Association in Chicago. Read the full story >>

Suggested Articles

The deal, which features an additional $2 billion in milestones, will give Bayer control of an AAV platform and a clinical-phase pipeline.

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.